eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

A vizsgálat adatai

Ki végzi

GlaxoSmithKline

Azonosító

NCT07177339EU 2025-521108-23-00

A regiszteradat frissítve

2026. július 28.

Eredeti leírás

Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.A teljes eredeti leírásKevesebb

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study of the Efficacy and Safety of Early Depemokimab Initiation as add-on Treatment in COPD Patients With Type 2 Inflammation

Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.

Bevonási feltételek: Male or eligible female participants; Eosinophilic phenotype measured using Blood Eosinophil Count (BEC); Moderate to severe COPD, defined as; A clinically documented history of COPD for at least 1 year; A post-salbutamol Forced expiratory volume in one second (FEV1)/Forced vital capacity (FVC) ratio of less than (<)0.70 and a post-salbutamol FEV1 greater than (>)30 percent (%) and <80% predicted normal values; Elevated risk for exacerbations, defined as; A well-documented history of only 1 moderate COPD exacerbation in the prior 12 months and; The presence of risk factors for future exacerbations/deterioration such as:; Modified Medical Research Council (mMRC) dyspnea score >= 2; COPD Assessment Test (CAT) >= 15; Post-bronchodilator FEV1 < 50% predicted; Chronic bronchitis; Smoking status: Current or former cigarette smokers with a history of cigarette smoking of >=10 pack-years at Screening; Dual (Inhaled corticosteroid (ICS)+ Long-acting beta2-adrenergic receptor agonist [LABA] or LABA+ Long-acting muscarinic receptor antagonist [LAMA]) or triple (ICS+LABA+LAMA) inhaler therapy as assessed by the investigator for at least 3 months; Body mass index (BMI) >=16 kilograms per square meter (kg/m\^2).

Kizáró feltételek: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of lung disease, and clinical manifestations of lung disease where primary diagnosis is not COPD are excluded; Participants with a current or prior physician diagnosis of asthma; Participants with childhood asthma are permitted, provided that childhood asthma has resolved before 18 years of age and has not recurred; COPD severity: Participants with more than one moderate exacerbation or severe exacerbation in the past 12 months prior to Visit 1; COPD stability: Participants with pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Visit 1; Pulmonary rehabilitation: Participants in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1; Other clinically significant lung disease: The Investigator must judge that COPD is the primary diagnosis accounting for the clinical manifestations of the lung disease; Lung resection: Participants with a history of, or plan for lung volume reduction surgery/endobronchial valve procedure; Chronic hypercapnia requiring non-invasive positive pressure ventilation (NIPPV) use including Bi-Level Positive Airway Pressure (BiPAP) or Continuous Positive Airway Pressure (CPAP) are excluded; Continuous oxygen: Participants requiring oxygen supplementation for COPD.

ClinicalTrials.gov NCT07177339 · EU CTIS 2025-521108-23-00